OCUL101

Also used as a comparator or background therapy in 1 trial

Phase	Registry id	Dates	Indication	Sponsor	Status	Outcome
Phase 2/3	NCT07520318 Comparator	Apr 2026 → Feb 2029 expected	wet macular degeneration	Shenzhen Oculgen Biomedical Technology Co., Ltd.	Not yet recruiting	No outcome recorded

Every value below carries the sentence it was read from. 1 source stands behind the page.

Field	Value	Cited text
Known as	OCUL101	“Oculgen has begun a study of an investigational drug called OCUL101 as a possible treatment for neovascular AMD.” NCT07520318 ↗
Action	Inhibit	“OCUL101 works by blocking both VEGF-A and C5.” NCT07520318 ↗
Modality	Protein / enzyme biologic	“OCUL101, an Anti-VEGF and Anti-Complement C5, Bi-specific Humanized Antibody-Like "Trap"” NCT07520318 ↗